These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 27234887

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X, Lv Y, Liu P, Li Z, Hu L, Zeng C, Yang L.
    Bioorg Med Chem Lett; 2016 Mar 15; 26(6):1571-1575. PubMed ID: 26879314
    [Abstract] [Full Text] [Related]

  • 3. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zhang M, Wang Y, Wang J, Liu Z, Shi J, Li M, Zhu Y, Wang S.
    Chem Pharm Bull (Tokyo); 2020 Mar 15; 68(10):971-980. PubMed ID: 32999149
    [Abstract] [Full Text] [Related]

  • 4. Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
    Patel HM, Pawara R, Ansari A, Noolvi M, Surana S.
    Bioorg Med Chem; 2017 May 15; 25(10):2713-2723. PubMed ID: 28366268
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. 6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Zhang Y, Chen L, Xu H, Li X, Zhao L, Wang W, Li B, Zhang X.
    Eur J Med Chem; 2018 Mar 10; 147():77-89. PubMed ID: 29421573
    [Abstract] [Full Text] [Related]

  • 7. Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold.
    Hu J, Han Y, Wang J, Liu Y, Zhao Y, Liu Y, Gong P.
    Bioorg Med Chem; 2018 May 01; 26(8):1810-1822. PubMed ID: 29486953
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
    Yan Q, Chen Y, Tang B, Xiao Q, Qu R, Tong L, Liu J, Ding J, Chen Y, Ding N, Tan W, Xie H, Li Y.
    Eur J Med Chem; 2018 May 25; 152():298-306. PubMed ID: 29730192
    [Abstract] [Full Text] [Related]

  • 11. Discovery of novel 4-arylamino-quinazoline derivatives as EGFRL858R/T790M inhibitors with the potential to inhibit the non-small cell lung cancers.
    Gan W, Wang C, Pan Q, Li Y, Guo Y, Fan D, Peng Y, Rao Z, Xu S, Zheng P, Zhu W.
    Bioorg Chem; 2022 Oct 25; 127():105994. PubMed ID: 35792314
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Chen L, Zhang Y, Liu J, Wang W, Li X, Zhao L, Wang W, Li B.
    Eur J Med Chem; 2017 Sep 29; 138():689-697. PubMed ID: 28711703
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
    Zhou W, Liu X, Tu Z, Zhang L, Ku X, Bai F, Zhao Z, Xu Y, Ding K, Li H.
    J Med Chem; 2013 Oct 24; 56(20):7821-37. PubMed ID: 24053674
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
    Pawara R, Ahmad I, Nayak D, Wagh S, Wadkar A, Ansari A, Belamkar S, Surana S, Nath Kundu C, Patil C, Patel H.
    Bioorg Chem; 2021 Oct 24; 115():105234. PubMed ID: 34399322
    [Abstract] [Full Text] [Related]

  • 19. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
    Zhang L, Yang Y, Zhou H, Zheng Q, Li Y, Zheng S, Zhao S, Chen D, Fan C.
    Eur J Med Chem; 2015 Sep 18; 102():445-63. PubMed ID: 26310890
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H2S) donors as potent EGFR inhibitors against L858R resistance mutation.
    Zheng YG, Zhang WQ, Meng L, Wu XQ, Zhang L, An L, Li CL, Gao CY, Xu L, Liu Y.
    Eur J Med Chem; 2020 Sep 15; 202():112522. PubMed ID: 32619886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.